NILE
08 Dec 2020
Trial Summary
A phase III, randomised, open-label, controlled, multi-centre, global study of first-line durvalumab in combination with standard of care chemotherapy and durvalumab in combination with tremelimumab and standard of care chemotherapy in patients with unresectable Urothelial Cancer.
Acronym:
NILE
ACTRN/NCT /ethics:
NCT03682068
Scientific title:
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)
Sponsor / Cooperative group:
AstraZeneca
Trial & Patient Characteristics
| Cancer Type | Bladder |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Urothelial Cancer |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2018-09-27 |
| Anticipated End Date | 2024-03-29 |
Participating Hospitals
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Christopher Hocking |
| Recruitment Status | Recruiting |